Literature DB >> 1616841

Cyclosporine in the treatment of azathioprine-induced red cell aplasia following renal transplantation.

B Vogt1, B A Fivush.   

Abstract

Azathioprine, a well-known immunosuppressive agent, is used extensively in renal transplantation. There have been several case reports of pure red cell aplasia induced by this drug following a successful kidney transplant. Previous management of azathioprine-induced red cell aplasia included reduction of azathioprine dose, or treatment with cyclophosphamide. We propose the substitution of cyclosporine for azathioprine, in this clinical setting. Not only does cyclosporine allow recovery of bone marrow function, but it maintains a level of immunosuppression which stabilizes renal function in the post-transplant patient.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616841     DOI: 10.1007/bf00878378

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

Review 1.  Cyclosporine.

Authors:  B D Kahan
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

2.  Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation.

Authors:  S N Wickramasinghe; H Dodsworth; R M Rault; B Hulme
Journal:  Transplantation       Date:  1974-11       Impact factor: 4.939

3.  Relative macrocytosis in cyclophosphamide and azathioprine therapy.

Authors:  J H Klippel; J L Decker
Journal:  JAMA       Date:  1974-07-08       Impact factor: 56.272

4.  The metabolism of azathioprine in renal failure.

Authors:  J F Bach; M Dardenne
Journal:  Transplantation       Date:  1971-10       Impact factor: 4.939

5.  Erythroid toxicity of azathioprin. Macrocytosis and selective marrow hypoplasis.

Authors:  B P McGrath; L S Ibels; E Raik; M J Hargrave
Journal:  Q J Med       Date:  1975-01

6.  Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient.

Authors:  D E Hogge; D R Wilson; K H Shumak; D C Cattran
Journal:  Can Med Assoc J       Date:  1982-03-01       Impact factor: 8.262

7.  The 1989 report of the North American Pediatric Renal Transplant Cooperative Study.

Authors:  S R Alexander; G S Arbus; K M Butt; S Conley; R N Fine; I Greifer; A B Gruskin; W E Harmon; P T McEnery; T E Nevins
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

8.  Cancers following cyclosporine therapy.

Authors:  I Penn
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939

9.  Azathioprine-induced pure red blood cell aplasia.

Authors:  C W Old; E P Flannery; T M Grogan; W H Stone; R P San Antonio
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

10.  Macrocytosis and pure RBC anemia caused by azathioprine.

Authors:  Y A DeClerck; R B Ettenger; J A Ortega; A J Pennisi
Journal:  Am J Dis Child       Date:  1980-04
  10 in total
  1 in total

Review 1.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.